A biotechnology company with clinical operations developing psychedelic medicine to treat Addiction.
With a dual strategic focus:
Development: Research & develop psychedelic drugs, therapies, and enabling technologies to treat Addiction.
Delivery: Treating Addiction and other mental health conditions in a chain of medical psychedelic clinics across Europe and through licensing partnerships in North America.
How Big Is The Market?
The global substance Addiction treatment industry is valued at USD17.5bn per annum and is forecast to increase to USD31.5bn per annum by 2027.
US accounts for 40% of this market, Europe 30%, Rest of World 20%.
Alcohol Use Disorder accounts for 30% of the treatment market, with tobacco and prescription medication also accounting for significant proportions.
Mental health and addictions are the 5th leading cause of illness globally, affecting 20% of the global population. It costs the EU, US, and UK economies US$1.5trn in lost economic activity per annum.
How Does Awakn Plan To Address This Market?
By Developing psychedelic drugs and therapies to better treat Addiction and Delivering psychedelic treatment in our clinics and through our partnerships.
Awakn is developing a range of targeted next generation drugs, therapies, and enabling technologies to treat several poorly addressed substance and behavioral addictions.
How Is This Done?
Drug development -Psychedelic drug discovery and development for treating substance and behavioural Addiction.
Therapy Development: Developing enabling technologies to improve the effectiveness and efficiency of Psychedelic–Assisted Psychotherapy in treating Addiction.
Clinics – Providing hope for those for whom the status quo is not working by combining the proven therapeutic potential of psychedelics with psychotherapy to treat Addiction and other mental health conditions.
20 clinics across Europe by end 2024
2021: London, Manchester, Bristol
2022: Birmingham, London #2, 3x more UK clinics, Dublin (Ireland)
2023 - 2024: Continental Europe
Each clinic to generate between $3M - $6M CAD operating at capacity per annum
Partnerships - Scaling our reach beyond our core territories through licensing and partnerships to enable Addiction treatment practitioners deliver the Awakn methodology.